Full Breakdown
U.S. Government Pushes for Drug Pricing Reform Amid Legal Challenges
3/20/2026, 4:48:51 PM
Legislative Efforts on Drug Pricing
The U.S. government is actively engaging pharmaceutical companies to build consensus around legislation aimed at codifying President Donald Trump's most-favored-nation (MFN) drug pricing policy into law. Chris Klomp, chief counsel at the U.S. Department of Health and Human Services (HHS), stated that the administration is working to ensure that U.S. patients, who often pay significantly more for prescription medications than those in other developed nations, can access more affordable drugs. The administration has already reached agreements with 16 major drugmakers to reduce prices for Medicaid and cash-paying patients. Klomp emphasized the importance of involving pharmaceutical companies in the legislative process to foster cooperation.
Legal Challenges Facing Major Drugmakers
In a related development, a U.S. appeals court has revived a whistleblower lawsuit against four major pharmaceutical companies—AbbVie, AstraZeneca, Novartis, and Sanofi—accusing them of defrauding federal and state governments by overcharging for medications supplied to low-income and uninsured patients. The 9th U.S. Circuit Court of Appeals ruled that these companies must defend themselves against claims of violating the federal False Claims Act through their involvement in the Section 340B Drug Pricing Program. This program allows certain healthcare providers to purchase drugs at significantly reduced prices, sometimes as low as one cent. The lawsuit, brought by Adventist Health System/West, alleges that these overcharges resulted in inflated reimbursements from Medicare and Medicaid.
Implications of Drug Pricing Policies
The ongoing scrutiny of drug pricing practices is not limited to domestic issues. As President Trump advocates for fair pricing from other nations, Japan's drug pricing policies have come under fire. Congressional aides have indicated that Japan's approach to pricing could become a significant point of contention during upcoming trade discussions. Lawmakers are concerned that Japan's pricing strategies undermine U.S. efforts to ensure that American patients do not pay more for medications than their counterparts in other wealthy countries. Former Rep. Michael Burgess has urged the administration to prioritize drug pricing in negotiations with Japan, emphasizing the need for equitable contributions to pharmaceutical innovation costs.
Criticism of Pharmaceutical Practices
Critics have raised concerns about the practices of pharmaceutical companies, particularly regarding the pricing of essential medications. For instance, GlaxoSmithKline (GSK) faced backlash after discontinuing a popular asthma inhaler, replacing it with a higher-priced version to avoid Medicaid rebates. This maneuver reportedly led to increased financial burdens for families and restricted access to necessary treatments. Senator Maggie Hassan highlighted the negative consequences of GSK's actions, which prompted health plans to impose barriers to access.
Conflicting Reports & Gaps
While the appeals court ruling allows the whistleblower lawsuit to proceed, there are discrepancies in the responses from the pharmaceutical companies involved. Representatives for AbbVie, AstraZeneca, Novartis, and Sanofi have declined to comment on the ruling, leaving questions about their defense strategies unanswered. Additionally, the broader implications of the proposed MFN pricing legislation remain uncertain, as some lawmakers view it as government overreach that contradicts free-market principles.
Verbatim Quotes
- “We're also beginning to read in pharmaceutical companies to help them understand the nature of the legislative text, to see if they can buy in, if there's a version we might reach,” — Chris Klomp, Chief Counsel, U.S. Department of Health and Human Services
- “Congress is going to be livid if Japan keeps freeloading off American innovation,” — Congressional Source
- “) made the case in the Reporter that the Administration should prioritize drug pricing in its negotiations with Japan: “President Trump has made clear that no American should pay more for a prescription drug than a citizen of any other wealthy country.” — Former Rep. Michael Burgess
The U.S. government's efforts to reform drug pricing are unfolding against a backdrop of legal challenges and international scrutiny, highlighting the complexities of ensuring affordable healthcare while balancing the interests of pharmaceutical companies.
